

Poelmans, Jennifer and Himmelreich, Uwe and Vanherp, Liesbeth and Zhai, Luca and Hillen, Amy and Holvoet, Bryan and Belderbos, Sarah and Brock, Matthias and Maertens, Johan and Velde, Greetje Vande and Lagrou, Katrien (2018) A multimodal imaging approach enables in vivo assessment of antifungal treatment in a mouse model of invasive pulmonary aspergillosis. *Antimicrobial Agents and Chemotherapy* . AAC.00240-18. ISSN 0066-4804

Access from the University of Nottingham repository:

http://eprints.nottingham.ac.uk/52384/1/Poelmans%20et%20al_A%20multimodal%20imaging%20approach.pdf

Copyright and reuse:

The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

This article is made available under the University of Nottingham End User licence and may be reused according to the conditions of the licence. For more details see: http://eprints.nottingham.ac.uk/end_user_agreement.pdf

A note on versions:

The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.

For more information, please contact eprints@nottingham.ac.uk

A multimodal imaging approach enables *in vivo* assessment of antifungal treatment in a mouse model of invasive pulmonary aspergillosis

Jennifer Poelmans,^{a,c} Uwe Himmelreich,^{a,c} Liesbeth Vanherp,^{a,c} Luca Zhai,^{a,c} Amy Hillen,^{a,c*} Bryan Holvoet,^{b,co} Sarah Belderbos,^{a,c} Matthias Brock,^d Johan Maertens,^e Greetje Vande Velde,^{a,c#} Katrien Lagrou,^f

^aBiomedical MRI unit, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium;

^bNuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.

^cMoSAIC, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.

^dFungal Biology Group - School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.

^eHematology, Department of Immunology and biology, KU Leuven, Leuven, Belgium.

^fLaboratory of Clinical Bacteriology and Mycology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.

Running Title: Multimodal imaging of IPA treatment in a mouse model

#Address correspondence to prof. Greetje Vande Velde, greetje.vandavelde@kuleuven.be

*Present address: Amy Hillen, Department of Cell and Molecular Biology (CMB), Karolinska Institutet, Stockholm, Sweden.

^oPresent address: Bryan Holvoet, Terumo Europe, Leuven, Belgium.

G.V.V. and K.L. contributed equally to this work.

Abstract

Aspergillus fumigatus causes life-threatening lung infections in immunocompromised patients. Mouse models are extensively used in research to assess the *in vivo* efficacy of antifungals. In recent years, there has been an increasing interest in the use of non-invasive imaging techniques to evaluate experimental infections. However, single imaging modalities have limitations concerning the type of information they can provide. In this study, magnetic resonance imaging and bioluminescence imaging were combined to obtain longitudinal information on the extent of developing lesions and fungal load in a leucopenic mouse model of IPA. This multimodal imaging approach was used to assess changes occurring within lungs of infected mice receiving voriconazole treatment starting at different time points after infection. Results showed that IPA development depends on the inoculum size used to infect animals and that disease can be successfully prevented or treated by initiating intervention during early stages of infection. Furthermore, we demonstrated that reduction of the fungal load is not necessarily associated with the disappearance of lesions on anatomical lung images, especially when antifungal treatment coincides with immune recovery. In conclusion, multimodal imaging allows to investigate different aspects of disease progression or recovery by providing complementary information on dynamic processes, which are highly useful for assessing the efficacy of (novel) therapeutic compounds in a time- and labor-efficient manner.

Introduction

Aspergillus fumigatus is an opportunistic pathogen which is ubiquitous in the environment (1). Inhalation of fungal spores can result in invasive pulmonary aspergillosis (IPA), especially in patients with prolonged neutropenia or underlying hematopoietic malignancies (2-5). Voriconazole and isavuconazole are recommended first line treatment options for invasive aspergillosis (6, 7). In addition to antifungal treatment, reversal of the underlying immunosuppression is also a key element in the successful management of IPA (7).

Preclinical research plays an important role in investigating the pathogenesis of IPA and in testing antifungal treatment strategies. In a previous study, we showed that anatomical imaging techniques such as magnetic resonance imaging (MRI) and computed tomography (CT) are highly suitable to monitor dynamic disease-related changes in a leucopenic mouse model of IPA (8). The non-invasive character of these techniques did not only allow for the longitudinal visualization of developing lung lesions, but also for the quantification of imaging-derived biomarkers such as the lung tissue volume. However, besides obtaining insight into structural changes occurring in the lung upon infection, it is also crucial to obtain information on fungal growth in order to fully comprehend all aspects of developing disease and treatment response. As an alternative for standard invasive techniques such as colony-forming unit (CFU) counting to assess infection, there has been great interest in using non-invasive imaging techniques to quantify the fungal load.

Bioluminescence imaging (BLI) is an optical technique based on the detection of photons, which are generated by an enzymatic reaction upon luciferin substrate administration (9). To apply this imaging modality in the infectious diseases field, pathogens have to be genetically modified to express the luciferase enzyme. As only

viable cells can produce bioluminescent signals, the detected signal can be used to determine dynamic changes in the microbial load of an organ. Therefore, the obtained read-outs are comparable to results obtained by conventional CFU counting (10). BLI has already been used extensively to study bacterial and viral infections in both superficially located organs such as the skin and deeply located organs such as the lungs (11-19). Unfortunately, transforming fungi to express luciferase turned out to be more challenging. Initial studies focused on the transformation of *Saccharomyces cerevisiae* and *Candida albicans* (20, 21). *In vivo*, only partial success was obtained with the bioluminescent *C. albicans* strain using *Renilla* or surface-anchored *Gaussia* luciferase (22-25). It proved to be feasible to monitor superficial infections, but limitations in the availability of the substrate coelenterazine and absorption of the emitted light (480 nm) by hemoglobin hampered the detection of deep-seated infections. These difficulties were overcome by using a codon-optimized firefly luciferase, which enabled to study disseminated candidiasis and revealed an unexpected persistence of *C. albicans* in the gall bladder under antifungal therapy (26). The firefly luciferase has also been successfully used to monitor invasive aspergillosis caused by *A. fumigatus* (10). In a first approach of using the bioluminescent strain, it was possible to visualize the early stages of disease in a cortisone-induced mouse model of IPA. However, imaging of late stage disease was hampered by restrictions in oxygen and substrate availability at the lesion site due to the strong inflammatory response and associated necrosis. Further studies revealed that the choice of immune suppressive regimen has an important impact on the evolution of bioluminescence during progression of disease (27). In contrast to the cortisone model, disease progression in cyclophosphamide-induced mice was associated with a strong increase in BLI signal over time due to rapid fungal growth and lung tissue invasion.

Furthermore, it was shown that animals treated with lipid amphotericin or voriconazole show a transient increase in BLI signal, followed by a clear decrease in case of treatment success (28). These results highlight the added value of using BLI for obtaining information on changes in fungal burden occurring within the lungs of leucopenic mice suffering from IPA.

In most studies, single imaging techniques are used to assess disease progression and treatment response, which strongly limits the amount and type of acquired information (8, 10, 28). In this study, both an optical and anatomical imaging technique were combined to non-invasively obtain complementary information on IPA development in a leucopenic mouse model. Furthermore, the influence of voriconazole treatment on both the fungal load and lesion size was longitudinally investigated. The aim of this study was to improve our knowledge on the relationship between detected lesion and fungal growth in a completely non-invasive manner.

Materials and Methods

Fungal strain

The bioluminescent *Aspergillus fumigatus* strain 2/7/1 was used (28). The strain was cultured for 3 days at 42°C on diluted Sabouraud agar, containing 10% of the dextrose and peptone concentrations used in regular Sabouraud agar. Conidia were harvested by flooding the agar with saline-0.1% Tween 80 (Sigma-Aldrich, Diegem, Belgium) and gently scraping the surface. The collected suspension was shaken vigorously for 5 minutes and spores were counted with a Neubauer haemocytometer. The suspension was diluted to a final concentration of 2.5×10^7 spores/ml or 1.0×10^7 spores/ml.

Mouse model

All animal experiments were carried out in compliance with national and European regulations and were approved by the animal ethics committee of KU Leuven. Ten-week old male BALB/c mice (Janvier, Le Genest, France) were rendered leucopenic by intraperitoneal (IP) injections of 150 mg/kg cyclophosphamide (Sigma-Aldrich, Diegem, Belgium) on day 4 and 1 prior to infection. To confirm leucopenia, blood was collected from a subset of animals by cardiac puncture and 3.8% trisodium citrate dihydrate was added to the sample to prevent coagulation. White blood cells were counted on day 0 ($n = 3$) and day 4 ($n = 3$) using the Advia 2120i hematology system (Siemens Healthcare GmbH, Erlangen, Germany).

On day 0, the animals were anesthetized with 1.5-2% isoflurane (Abbott Laboratories, Queenborough, UK) in 100% oxygen and intranasally instilled with 20 μ l of a suspension containing either 5×10^5 (high inoculum) or 2×10^5 (low inoculum) *A. fumigatus* spores, as previously described (8). Directly after instillation, the mice were positioned upright until normal breathing was resumed. In this manuscript, all times are stated relative to the day of inoculation, which will be referred to as day 0.

All animals in the treatment groups received daily IP injections of 20 mg/kg voriconazole (Vfend®, Pfizer, New York, USA) dissolved in saline. For the high inoculum group, treatment was initiated either on the day of infection (day 0; n = 5) or on day 1 (n = 5), day 2 (n = 5) or day 3 (n = 5) post infection (PI). Based on the data obtained for this high inoculum group, treatment was initiated directly on the day of infection (day 0; n = 5) or on day 2 PI (n = 5) for the low inoculum group. To prevent rapid metabolization of voriconazole, the drinking water was replaced by 100% grape fruit juice (Carrefour brand, Boulogne Billancourt, France) as described before (29). The disease course was monitored by acquiring MRI scans before infection (baseline) and on day 1, 2, 3, 4, 5 and 14 PI. In addition, *in vivo* BLI scans were acquired on day 3, 5 and 9 PI. Non-treated animals (n = 10 for the high inoculum group; n = 5 for the low inoculum group) did not receive voriconazole nor grape fruit juice. For these mice, daily MRI and *in vivo* BLI scans were acquired until day 4 PI for the high inoculum group and until day 7 PI for the low inoculum group.

During image acquisition, the mice were anesthetized with 1.5-2% isoflurane in 100% O₂ administered via a nasal cone. Body weight, posture and body temperature were monitored daily. The animals were sacrificed when humane endpoints were reached, including a strong loss in body weight (> 25%), lethargy and labored breathing. For all treatment groups, the remaining animals that did not reach the humane endpoints were euthanized after the last imaging time point. After sacrificing, *ex vivo* BLI scans of the isolated lungs were acquired.

Bioluminescence Imaging

Images were acquired using an IVIS Spectrum system (Perkin Elmer). For *in vivo* imaging, anesthetized animals were placed in the flow chamber and D-luciferin was injected subcutaneously (126 mg/kg). Next, images were acquired until the peak signal

intensity was reached. For *ex vivo* imaging, the complete lungs were inflated with 500 μ l D-luciferin (7.5 mg) by inserting a catheter (22-gauge) into the trachea, after which the tissue was isolated and immediately placed in the flow chamber to perform a scan. The BLI images were processed using the Living Image software (version 4.5.4, Perkin Elmer, Hopkinton, USA). A circular region of interest (ROI) covering the complete lung area was used to measure the total photon flux.

Magnetic Resonance Imaging

Images were acquired on a 9.4 Tesla Biospec small animal MRI scanner (20 cm horizontal bore size; Bruker BioSpin, Ettlingen, Germany) using a gradient insert (maximal field strength of 1200 mT/m) and a 3.5 cm quadrature resonator. Body temperature and breathing rate were continuously monitored and kept at physiological values during the scans by using a physiological monitoring system (SAll, Stony Brook, NY, USA). A 3D prospectively respiratory gated ultrashort echo time (UTE) pulse sequence was used with following parameters: 0.03 ms echo time (TE), 15 ms repetition time (TR), 5° flip angle (FA), 3.5 cm isotropic field of view (FOV), 128 x 128 x 128 matrix, 273 μ m isotropic resolution and a total acquisition time of 18 minutes (8).

The acquired MR images were analyzed using an in-house written Mevislab module (version 2.6.1; Mevislab Medical Solutions and Fraunhofer MEVIS, Bremen, Germany). The lung tissue volume was quantified based on a volume of interest (VOI) covering the complete lung by manually delineating a ROI on each image slice, excluding the heart and main pulmonary vessels. Based on the receiver gain value of individual scan, a variable threshold was used to select all voxels with a signal intensity above this threshold. Furthermore, a cumulative image score was determined to semi-quantitatively describe lesion development and progression by applying a previously described scoring system (8).

Fungal load quantification

After the last imaging time point, all animals were euthanized by an overdose of pentobarbital (Nembutal, CEVA Santé Animale, Diegem, Belgium). After performing *ex vivo* BLI, the right lung lobes were removed for fungal load quantification by colony-forming unit (CFU) counting. The lungs were weighed and homogenized in 600 μ l phosphate-buffered saline (PBS). Fivefold dilution series were prepared and plated on Sabouraud agar, followed by three days incubation at 30°C and manual counting of CFUs (30).

Histological analysis

The left lung lobe was isolated, post-fixed (24 hours in 10%-formalin) and embedded in paraffin. The entire lung was sectioned (5 μ m) and stained with periodic acid-Schiff (PAS), staining fungi in red (31).

Statistics

The data were analyzed using Prism (version 5.04; GraphPad software, San Diego, CA). Repeated measures ANOVA with a Tukey's post-test was used to investigate changes in total photon flux (BLI), lung tissue volume and cumulative image score (MRI) over time in the non-treated high inoculum group. Linear regression analysis was performed to assess the correlation between BLI and MRI derived biomarkers. Student's t-test was used to evaluate differences in total photon flux (*ex vivo* BLI) and CFU counts between the treated and non-treated groups. Differences were considered statistically significant if p -value < 0.05. In all figures, the data is represented as mean \pm standard deviation (SD).

Results

Longitudinal assessment of fungal load and lung anatomy changes by combining MRI and BLI

In this study, mice were rendered leucopenic by two injections of cyclophosphamide. All circulating white blood cells were depleted at the time of infection, meaning there were 37.0 ± 6.4 neutrophils, 96.3 ± 33.9 lymphocytes, 0 ± 0 monocytes, 3.7 ± 6.4 eosinophils and 0 ± 0 basophils / μl present in the blood. In leucopenic mice, pulmonary infection is characterized by excessive hyphal growth (32). In order to mimic clinic management where reversal of immunosuppression is needed for clearance of the fungal infection, no additional boosters of cyclophosphamide post infection were administered. Consequently, the immune system recovered by day 4, which was reflected by a mean neutrophil count of 162.9 ± 23.12 cells / μl blood.

Visual assessment of the MR images revealed the presence of hyper intense lesions within the infected lungs on day 3 and 4 post infection (figure 1A). Both the lung tissue volume and cumulative image score quantified from these MR images increased over time, reaching significance on day 3 and 4 compared to baseline (figures 1B-C). Upon visual inspection of the corresponding bioluminescence images, high signal intensities emerged from the lung area on day 3 and 4 after instillation (figure 1D). Furthermore, a bioluminescent signal appeared in the nose region starting from day 2. The total photon flux quantified from the lung region increased over time, becoming significant from day 2 onwards (figure 1E). After comparing BLI and MRI derived parameters, a strong positive correlation was identified between the total photon flux and the lung tissue volume ($R^2 = 0.65$) and between the total photon flux and cumulative image score ($R^2 = 0.76$) (figure 2A-B). By performing *in vivo* BLI, longitudinal information was

obtained on the amount of viable fungal cells present in the lesions detected on the anatomical MR images of infected mouse lungs.

Non-invasive detection of changes in lesion composition resulting from antifungal treatment

The combination of both imaging modalities could also be used to obtain a better understanding of the effect of antifungal treatment on the development and composition of lung lesions. To assess differences in therapy response, voriconazole treatment was initiated on the day of infection (day 0) or on day 1, 2, 3 after infection with a high inoculum. The general condition of the animals was monitored daily and anatomical lung MR images were acquired on day 1-5 and 14. None of the animals receiving treatment starting at day 3 survived longer than 4 days post infection (figure 3A). The MR lung images of these animals showed detectable lesions starting from day 3 (figure 3C-D, light grey bars). Initiating treatment earlier after infection strongly improved the survival rates, as 60% of animals treated from day 2 survived until day 14 (figure 3A). However, the MRI scans revealed a gradual increase of lung lesions over time in all animals, proving that treatment did not prevent disease progression in this group (figure 3B-D; second row - medium grey bars). Animals receiving treatment from day 1 post infection also displayed an improved survival rate (figure 3A). Unlike the previous groups, most mice did not develop MR-detectable lesions within the lungs (figure 3B, third row). Only two animals out of five showed clear lesion development and needed to be sacrificed by day 4 or 5. As a result, both quantitative MRI-derived biomarkers increased on day 4 and 5, followed by a strong decrease by day 14 (figure 3C-D, dark grey bars). When voriconazole treatment was started immediately after infection, 80% of the animals survived until day 14 (figure 3A). Only a limited amount

of small lesions developed within the lungs of these animals (figure 3B-D; fourth row - black bars).

The MRI results of the different treatment groups demonstrated a clear relationship between the timing of treatment initiation and lesion development rate. To obtain information on potential changes in the fungal load during treatment, *in vivo* BLI scans were acquired on day 3, 5 and 9. Intense BLI signals were observed in the lung area of animals receiving treatment starting from day 3 (figure 4A). All animals of this treatment group needed to be sacrificed at the latest by day 4, explaining the lack of data on later time points (figure 4B). Animals receiving treatment starting from day 2 also showed clear BLI signal from the lung region on day 3 (figure 4C). This signal seemed to decrease by day 5 and returned to background levels by day 9 (figure 4D). The quantified values were an order of magnitude lower on day 3 compared to the group with treatment starting at day 3. The majority of animals in which treatment was initiated on day 1 did not show any bioluminescent signal on day 3, 5 and 9 (figure 4E-F). However, the two animals showing lesions on the lung MR images also displayed clear BLI signal originating from the lung region on day 3. As these animals had to be sacrificed by day 5, no BLI data was available on later time points. None of the animals receiving treatment from day 0 showed any detectable BLI signal from the lung area (figure 4G-H). Both MRI and BLI results indicate that initiation of treatment during the early stages of infection has a beneficial effect on both the survival and disease state of the animal.

Improved treatment success in animals infected with a low inoculum of spores

Therapy might affect disease progression differently when animals are infected with a low number of fungal spores, as this model is associated with a high inter-animal variation in infection development (8). To further assess this hypothesis, leucopenic

mice were instilled with 2×10^5 spores and voriconazole treatment was initiated on day 0 or day 2. The animals were followed-up by *in vivo* MRI (day 1-5 and 14) and *in vivo* BLI scans (day 3, 5, 9). A separate control group did not receive treatment and was scanned daily until day 7. Half of the non-treated mice needed to be sacrificed by day 4, while the remaining animals survived until day 7. Lesions could be visualized within the lungs of 80 % of the non-treated mice and quantified as an increase in lung tissue volume and cumulative image score over time (figure 5A-C). Furthermore, BLI signal was detected from the lung region of the majority of animals by day 4, associated by a decrease in BLI signal in the surviving mice (figure 5D-F). Within the lungs of mice receiving treatment from day 2, small lesions could be detected on the MR images from day 4 onwards (figure 5A-C; second row). However, no BLI signal could be detected from the lung region of any animal from this group (figure 5E-F). Animals receiving treatment from day 0 did not develop any detectable lesions within the lungs (figure 5A-C, F). These results show an improved therapeutic response in animals infected with a low inoculum, even if treatment is initiated at later time points post infection.

***Ex vivo* analysis of the lungs support the *in vivo* imaging findings**

After the last *in vivo* imaging time point, animals were euthanized and the lungs were isolated to perform *ex vivo* BLI, CFU counting and histology. The lungs of non-treated mice infected with a high inoculum showed a strong BLI signal, which was associated with high total photon flux values and a high amount of counted colonies (figure 6A-C, light grey). Comparable CFU counting results were obtained for the animals where treatment commenced on day 3 (figure 6C). On the contrary, no BLI signal could be detected from the lungs of mice receiving treatment from day 0 or 1 and no colonies could be grown from their lung tissue (figure 6A-C, black and dark grey). Animals

receiving treatment from day 2 displayed modest BLI signals in the lungs and significantly lower amounts of colonies could be grown from the tissue compared to the non-treated group (figure 6A-C, medium grey). For animals infected with a low inoculum, the lack of treatment (control group) resulted in a strong BLI signal, originating from the lungs (figure 7A-B, light grey). Furthermore, colonies could be grown from the lung tissue of most of the animals (figure 7C). In contrast, no clear BLI signal could be detected nor could any colony be grown from the lungs for both treatment groups (figure 7A-C, black and medium grey).

Histological analysis revealed the presence of large amounts of fungal elements within the lungs of non-treated animals infected with a high inoculum (figure 8A). Fungal hyphae invaded the airways and blood vessels, thereby destroying the bronchial lining and normal lung structure. Comparable results were obtained for the animals receiving treatment from day 3 onwards (data not shown). In contrast, no fungi were detectable within the lungs of animals receiving treatment during early stages of infection (figure 8B). Massive lung lesions were observed in the lungs of animals treated from day 2, which mainly consisted of immune cells and only a limited number of fungal elements (figure 8C). Infection with a low inoculum of fungal spores resulted in the development of lesions in the majority of non-treated animals, which contained large amounts of fungal elements (figure 8D). On the contrary, animals receiving treatment from day 0 and day 2 did not show clear lesions on histological lung sections (figure 8 E-F). In conclusion, the *ex vivo* analysis of the lungs confirmed the *in vivo* multimodal imaging results.

Discussion

This study revealed the potential of combining multimodal imaging approaches to study fungal disease development and treatment success. The acquired MR images revealed the development of extensive lesions within the lung, which is in line with our previously published results (8). In parallel, a strong increase in bioluminescence signal intensity was observed from the lung area during the course of disease. These observations indicate that the lung lesions detected by MRI are predominantly composed of viable fungal cells. Furthermore, a strong bioluminescence signal originating from the nose area likely resulted from fungal colonization or infection of the nasopharynx or sinuses (28). Switching from an intranasal to an intratracheal model could potentially avoid this secondary infection. Multimodal imaging allowed us to non-invasively obtain dynamic information on both fungal load and lesion size in a leucopenic IPA mouse model, which is of interest when assessing the effect of antifungals.

We also investigated the feasibility to non-invasively monitor the effects of voriconazole treatment, including reductions of the fungal load and potential changes in lesion formation. Voriconazole was therefore administered at different time points after fungal spore instillation. Starting treatment at the latest stage of infection proved to be inefficient in counteracting disease progression. This is conform to the clinical situation, in which late start of treatment is associated to a poor survival rate (6). On the contrary, initiating treatment during the very first stages of infection successfully prevented IPA development. The survival rates improved drastically and no pathological changes could be detected within the lungs. These results support the clinical concept that early diagnosis and treatment administration are essential to successfully recover from IPA and underlines the importance of preemptive antifungal treatment in high-risk patient

populations. Furthermore, we showed that the treatment efficacy was higher in animals infected with a low inoculum, even when treatment was initiated as late as 48 hours after instillation. The fungal burden is generally lower in these mice, which facilitates controlling the infection by administration of antifungal compound in combination with the restoring immune system.

Most preclinical studies initiate treatment immediately after inducing infection, because it increases the success rate for obtaining a positive response. However, studying the delayed therapeutic effect of a compound is much more relevant, as it facilitates the translation of preclinical results into a clinical setting. Previous studies showed that non-invasive imaging techniques can only detect infection as early as 48 hours post instillation in the cyclophosphamide mouse model (8, 28). Based on this information, a true therapeutic treatment strategy was assessed in our imaging study by initiating voriconazole administration on day 2 post infection. The majority of animals survived for the total observation period of two weeks, which is indicative for treatment success. However, MR imaging revealed the clear development of lung lesions, which kept on increasing in size over time. The associated BL images showed a transient increase in lung signal, meaning that the lesions detected by MRI still contained a high amount of viable fungal cells up to 24 hours after the first administration of voriconazole. At later time points, the number of viable fungi decreased drastically, although lesions did not resolve on the MR images. Histopathological analysis of those lesions revealed a massive influx of immune cells at the lesion sites. All animals were rendered leucopenic at the time of infection, but no additional boosters of cyclophosphamide were administered. This resulted in recovery of the immune system by day 4 and enabled the development of the observed inflammatory response⁽³³⁾. Altogether, these findings demonstrate that the improvements observed in animals treated from day 2 resulted

from an interplay between the fungicidal effect of voriconazole and the inflammatory processes initiated upon reversal of leucopenia. This slows down lesion growth and leads to a change in lesion composition rather than the disappearance of induced lesions.

In clinical practice, decisions concerning discontinuation of antifungal treatment in IPA patients are based on several factors, including immune status and evidence of resolution of clinical signs and symptoms of disease (6, 7). In general, the improvement of lesions detected by CT is considered as strong evidence of treatment success. However, multiple clinical studies revealed that a worsening of pulmonary lesions is not necessarily associated with progressing IPA (34-36). Antifungal treatment is, whenever possible, combined with a reduction of immunosuppressive therapy to improve patient outcome, but neutrophil recovery can potentially result in the development of a pulmonary immune reconstitution inflammatory syndrome (IRIS). This syndrome causes a massive influx of immune cells at the site of infection, leading to an increase in lesion size and thus a worsening of radiological findings (34, 35). Both IRIS and refractory IPA are associated with an increase in lesion volume on CT images, making it difficult to distinguish between these two different conditions although both require different treatment approaches. There is a need to gather more information on IRIS in the context of IPA management and its impact on disease recovery. Preclinical research could play a role in assessing new treatment and management options, as it was shown in our study that a potential development of IRIS can non-invasively be identified in a leucopenic IPA mouse model by the combined use of BLI and MRI. However, further in depth studies are needed to confirm the development of IRIS and may require a larger number of animals and the use of additional markers. This can then be combined by the proposed multimodal imaging

approach to longitudinally assess the impact of adapting the treatment regimen on the lesion composition and outcome of the subject.

In conclusion, we showed that the combination of BLI and MRI is highly suitable to evaluate different aspects of progressing IPA in leucopenic mice, as it provides complementary information on dynamic changes in fungal load as well as lung lesion development. Furthermore, we were able to gain insights in therapy-induced changes concerning both the extent and the composition of lesions, which is crucial to fully comprehend different aspects of disease recovery or deterioration. We believe that multimodal imaging will become increasingly important in future preclinical studies as a tool to evaluate the *in vivo* efficacy of therapeutic compounds in a time-efficient manner.

Acknowledgements

This work was supported by funding provided by the Flemish research foundation (FWO; G.0691.15N and 1506114N) and KU Leuven IF and BOF (CREA/14/015, STG/15/024, C24/17/061). JP and BH received a PhD grant for strategic basic research from the Agency for Innovation by Science and Technology (IWT). LV is a SB PhD fellow at FWO. The work of MB was supported by the Transregio 124 FungiNet project A3 from the German Science Foundation (DFG). GVV received a postdoctoral fellowship from the FWO. Use of the bioluminescent *Aspergillus fumigatus* 2/7/1 strain was granted by the Leibniz Institute for Natural Product Research and Infection Biology (Hans Knöll Institute, Jena, Germany). All preclinical imaging was performed at the Molecular Small Animal Imaging Centre of KU Leuven.

References


1. Pasqualotto AC. 2010. Aspergillosis : from diagnosis to prevention, 1st ed. Springer, Dordrecht.
2. Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, Pastore D, Stanzani M, Cattaneo C, Fanci R, Caramatti C, Rossini F, Luppi M, Potenza L, Ferrara F, Mitra ME, Fadda RM, Invernizzi R, Aloisi T, Picardi M, Bonini A, Vacca A, Chierichini A, Melillo L, de Waure C, Fianchi L, Riva M, Leone G, Aversa F, Nosari A. 2010. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. *Haematologica* 95:644-50.
3. Feldmesser M. 2006. Role of neutrophils in invasive aspergillosis. *Infect Immun* 74:6514-6.
4. Silveira F, Paterson DL. 2005. Pulmonary fungal infections. *Curr Opin Pulm Med* 11:242-6.
5. Smith JA, Kauffman CA. 2012. Pulmonary fungal infections. *Respirology* 17:913-26.
6. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. *Clin Infect Dis* 46:327-60.
7. Patterson TF, Thompson GR, 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. 2016. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 63:e1-e60.
8. Poelmans J, Hillen A, Vanherp L, Govaerts K, Maertens J, Dresselaers T, Himmelreich U, Lagrou K, Vande Velde G. 2016. Longitudinal, *in vivo* assessment of invasive pulmonary aspergillosis in mice by computed tomography and magnetic resonance imaging. *Lab Invest* 96:692-704.
9. Gammon ST, Foje N, Brewer EM, Owers E, Downs CA, Budde MD, Leevy WM, Helms MN. 2014. Preclinical anatomical, molecular, and functional imaging of the lung with multiple modalities. *Am J Physiol Lung Cell Mol Physiol* 306:L897-914.
10. Brock M, Jouvion G, Droin-Bergere S, Dussurget O, Nicola MA, Ibrahim-Granet O. 2008. Bioluminescent *Aspergillus fumigatus*, a new tool for drug efficiency testing and *in vivo* monitoring of invasive aspergillosis. *Appl Environ Microbiol* 74:7023-35.
11. Demidova TN, Gad F, Zahra T, Francis KP, Hamblin MR. 2005. Monitoring photodynamic therapy of localized infections by bioluminescence imaging of genetically engineered bacteria. *J Photochem Photobiol B* 81:15-25.
12. Lu Z, Dai T, Huang L, Kurup DB, Tegos GP, Jahnke A, Wharton T, Hamblin MR. 2010. Photodynamic therapy with a cationic functionalized fullerene rescues mice from fatal wound infections. *Nanomedicine (Lond)* 5:1525-33.
13. Engelsman AF, van Dam GM, van der Mei HC, Busscher HJ, Ploeg RJ. 2010. *In vivo* evaluation of bacterial infection involving morphologically different surgical meshes. *Ann Surg* 251:133-7.
14. Francis KP, Yu J, Bellinger-Kawahara C, Joh D, Hawkinson MJ, Xiao G, Purchio TF, Caparon MG, Lipsitch M, Contag PR. 2001. Visualizing pneumococcal infections in the lungs of live mice using bioluminescent *Streptococcus pneumoniae* transformed with a novel gram-positive lux transposon. *Infect Immun* 69:3350-8.
15. Smith MW, Schmidt JE, Rehge JE, Orihuela CJ, McCullers JA. 2007. Induction of pro- and anti-inflammatory molecules in a mouse model of pneumococcal pneumonia after influenza. *Comp Med* 57:82-9.

16. Hertlein T, Sturm V, Jakob P, Ohlsen K. 2013. 19F magnetic resonance imaging of perfluorocarbons for the evaluation of response to antibiotic therapy in a *Staphylococcus aureus* infection model. PLoS One 8:e64440.
17. Luker KE, Hutchens M, Schultz T, Pekosz A, Luker GD. 2005. Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. Virology 341:284-300.
18. Luker GD, Prior JL, Song J, Pica CM, Leib DA. 2003. Bioluminescence imaging reveals systemic dissemination of herpes simplex virus type 1 in the absence of interferon receptors. J Virol 77:11082-93.
19. Cook SH, Griffin DE. 2003. Luciferase imaging of a neurotropic viral infection in intact animals. J Virol 77:5333-8.
20. Vieites JM, Navarro-Garcia F, Perez-Diaz R, Pla J, Nombela C. 1994. Expression and in vivo determination of firefly luciferase as gene reporter in *Saccharomyces cerevisiae*. Yeast 10:1321-7.
21. McNabb DS, Reed R, Marciniak RA. 2005. Dual luciferase assay system for rapid assessment of gene expression in *Saccharomyces cerevisiae*. Eukaryot Cell 4:1539-49.
22. Srikantha T, Chandrasekhar A, Soll DR. 1995. Functional analysis of the promoter of the phase-specific WH11 gene of *Candida albicans*. Mol Cell Biol 15:1797-805.
23. Srikantha T, Klapach A, Lorenz WW, Tsai LK, Laughlin LA, Gorman JA, Soll DR. 1996. The sea pansy *Renilla reniformis* luciferase serves as a sensitive bioluminescent reporter for differential gene expression in *Candida albicans*. J Bacteriol 178:121-9.
24. Nakayama H, Mio T, Nagahashi S, Kokado M, Arisawa M, Aoki Y. 2000. Tetracycline-regulatable system to tightly control gene expression in the pathogenic fungus *Candida albicans*. Infect Immun 68:6712-9.
25. Enjalbert B, Rachini A, VEDIYAPPAN G, Pietrella D, Spaccapelo R, Vecchiarelli A, Brown AJ, d'Enfert C. 2009. A multifunctional, synthetic *Gaussia princeps* luciferase reporter for live imaging of *Candida albicans* infections. Infect Immun 77:4847-58.
26. Jacobsen ID, Luttich A, Kurzai O, Hube B, Brock M. 2014. In vivo imaging of disseminated murine *Candida albicans* infection reveals unexpected host sites of fungal persistence during antifungal therapy. J Antimicrob Chemother 69:2785-96.
27. Ibrahim-Granet O, Jouvion G, Hohl TM, Droin-Bergere S, Philippart F, Kim OY, Adib-Conquy M, Schwendener R, Cavaillon JM, Brock M. 2010. In vivo bioluminescence imaging and histopathologic analysis reveal distinct roles for resident and recruited immune effector cells in defense against invasive aspergillosis. BMC Microbiol 10:105.
28. Galiger C, Brock M, Jouvion G, Savers A, Parlato M, Ibrahim-Granet O. 2013. Assessment of efficacy of antifungals against *Aspergillus fumigatus*: value of real-time bioluminescence imaging. Antimicrob Agents Chemother 57:3046-59.
29. Sugar AM, Liu XP. 2000. Effect of grapefruit juice on serum voriconazole concentrations in the mouse. Med Mycol 38:209-12.
30. Gupta VK, Tuohy MG. 2013. Laboratory protocols in fungal biology: Current methods in fungal biology. Springer New York, New York.
31. Roden AC, Schuetz AN. 2017. Histopathology of fungal diseases of the lung. Semin Diagn Pathol 34:530-549.
32. Dagenais TR, Keller NP. 2009. Pathogenesis of *Aspergillus fumigatus* in Invasive Aspergillosis. Clin Microbiol Rev 22:447-65.
33. Huyan XH, Lin YP, Gao T, Chen RY, Fan YM. 2011. Immunosuppressive effect of cyclophosphamide on white blood cells and lymphocyte subpopulations from peripheral blood of Balb/c mice. Int Immunopharmacol 11:1293-7.


- 519 34. Miceli MH, Maertens J, Buve K, Graziutti M, Woods G, Rahman M, Barlogie B,
520 Anaissie EJ. 2007. Immune reconstitution inflammatory syndrome in cancer patients
521 with pulmonary aspergillosis recovering from neutropenia: Proof of principle,
522 description, and clinical and research implications. *Cancer* 110:112-20.
- 523 35. Jung J, Hong HL, Lee SO, Choi SH, Kim YS, Woo JH, Kim SH. 2015. Immune
524 reconstitution inflammatory syndrome in neutropenic patients with invasive pulmonary
525 aspergillosis. *J Infect* 70:659-67.
- 526 36. Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L, Lopez J,
527 Couillault G, Piard F, Vagner O, Guy H. 2001. Increasing volume and changing
528 characteristics of invasive pulmonary aspergillosis on sequential thoracic computed
529 tomography scans in patients with neutropenia. *J Clin Oncol* 19:253-9.

530

Figures & figure legends



1 **Figure 1: Multimodal imaging of non-treated mice infected with a high inoculum**
2 **of *A. fumigatus* spores.** (A) Representative 3D-UTE MR images of the lung before
3 (Baseline) and after infection. (B-C) Graphs representing the lung tissue volume and
4 cumulative image score quantified from the 3D-UTE MR images. (D) Representative
5 BL images acquired before (Baseline) and after infection. (E) Graph representing the
6 total photon flux quantified from the BLI images based on a circular ROI covering the
7 complete lung region. Error bars represent SD of multiple mice (n = 10). *: p < 0.05; **: p < 0.01; ***: p < 0.001.



9 **Figure 2: Agreement between parameters quantified from BLI and MRI.** (A) Linear
10 regression analysis of the BLI-derived total photon flux versus the MRI-derived lung
11 tissue volume. (B) Linear regression analysis of the BLI-derived total photon flux versus
12 the MRI-derived cumulative image score, expressed in arbitrary units. Dashed lines
13 represent the 95% confidence band.




Figure 3: MR imaging of animals infected with a high inoculum of *A. fumigatus* spores receiving voriconazole at different time points. (A) Survival curve including all treatment groups. (B) Representative 3D-UTE MR images of the lung before (Baseline) and after infection of all treatment groups. (C-D) Graphs representing the lung tissue volume and cumulative image score quantified from the 3D-UTE MR images for all treatment groups. Error bars represent SD of multiple mice (n = 5 per treatment group). *: p < 0.05; **: p < 0.01; ***: p < 0.001.




Figure 4: Bioluminescence imaging of animals infected with a high inoculum of *A. fumigatus* spores receiving voriconazole from different time points. Representative BLI images and associated graphs showing the total photon flux of infected mice receiving treatment from day 3 (A-B), day 2 (C-D), day 1 (E-F) or immediately after infection (G-H). Error bars represent SD of multiple mice (n = 5 per treatment group).




Figure 5: Multimodal imaging of mice infected with a low inoculum of *A. fumigatus* spores. (A) Representative 3D-UTE lung MR images of non-treated animals and animals receiving voriconazole from day 2 or immediately after infection. (B-C) Graphs representing the lung tissue volume and cumulative image score quantified from the 3D-UTE MR images for all animal groups. (D) Representative BLI images of non-treated animals on day 3 and 4 after infection. (E) Representative BLI images of animals receiving treatment from day 2 on day 3, 5 and 9 after infection. (F) Graphs representing the total photon flux quantified from the BLI images for all animal groups. Error bars represent SD of multiple mice (n = 5 per animal group).




Figure 6: Ex vivo quantification of the fungal load for treated and non-treated animals infected with a high inoculum. (A) Representative *ex vivo* BLI images of lungs isolated after the last imaging time point. (B) Graph representing the total photon flux quantified from the *ex vivo* BLI images using a circular ROI covering the lungs. (C) Graph representing the amount of counted colonies per gram of lung tissue. Error bars represent SD. *: $p < 0.05$; **: $p < 0.01$; ***: $p < 0.001$.




Figure 7: Ex vivo quantification of the fungal load for treated and non-treated animals infected with a low inoculum. (A) Representative *ex vivo* BLI images of lungs isolated after the last imaging time point. (B) Graph representing the total photon flux quantified from the *ex vivo* BL images using a circular ROI covering the lungs. (C) Graph representing the amount of counted colonies per gram of lung tissue. Error bars represent SD.




Figure 8: Light microscopy images of PAS-stained lung sections. Representative images of mice infected with a high inoculum of fungal spores without treatment (A) or after receiving treatment from day 0 (B) or day 2 (C). Representative images of mice infected with a low inoculum of fungal spores without treatment (D) or after receiving treatment from day 0 (E) or day 2 (F). The scale bars (upper left corner) measure 100 μ m. For both high and low inoculum groups, the lungs of non-treated animals were isolated on day 4 and the lungs of treated animals on day 14 post infection.